Drugs / Tisleizumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07243938 | Jan 2026 → Jul 2028 expected | gastroesophageal junction adenocarcinoma, rectal carcinoma | Tao Zhang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06262581 | Sep 2023 → Nov 2024 | colorectal cancer | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tisleizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06262581 ↗ |
| Known as | BGB-A317 | “Drug: Tisleizumab(BGB-A317)” NCT07243938 ↗1“Tisleizumab(BGB-A317)” NCT06262581 ↗ |
| Action | Inhibit | “single anti-PD-1 (Tisleizumab-BGB-A317 ) neoadjuvant treatment” NCT06262581 ↗ |
| Route | Intravenous | “200mg i.v. q3w” NCT06262581 ↗ |